OKLAHOMA Health Care Authority | Serving Oklahomans through SoonerCare

March 25, 2024

RE: Renagel® and Fosrenol® Coverage Changes Effective April 8, 2024

The following changes will take effect April 8, 2024. Complete prior authorization (PA) criteria can be found on the OHCA website at www.oklahoma.gov/ohca/pa. Pharmacy PA forms can be found on the OHCA website at https://oklahoma.gov/ohca/rxforms.

Renagel® (Sevelamer Hydrochloride)
Renagel® (brand and generics) will require PA. Members currently utilizing Renagel® will need to switch to Renvela® (sevelamer carbonate) or a PA request may be submitted with reasoning why the member cannot use the sevelamer carbonate formulation. The PA criteria are as follows:

Renagel® (Sevelamer Hydrochloride) Approval Criteria:

1. An FDA approved indication for the control of serum phosphorus in members with chronic kidney disease (CKD) on dialysis; and
2. A patient-specific clinically significant reason why the member cannot use Renvela® (sevelamer carbonate) 800mg tablets or other phosphate binders available without prior authorization must be provided.

Fosrenol® (Lanthanum Carbonate)
Fosrenol® (lanthanum carbonate) will be brand preferred. Members currently utilizing generic lanthanum carbonate will need to switch to brand Fosrenol®.

The specific PA requirements for hyperphosphatemia medications can be found on the OHCA website in the “Chelating/Binding Agents” therapeutic category.

Generic calcium acetate containing products, brand name Fosrenol® (lanthanum carbonate chewable tablet and oral powder packet), PhosLo® (calcium acetate gel capsule), Phoslyra® (calcium acetate oral solution), and Renvela® (sevelamer carbonate tablet and packet for suspension) are currently available without PA.

Thank you for the service you provide to Oklahomans insured by SoonerCare!